PCAS Longjumeau, February 18th, 2016
in millions of euros
2014
2015
% change
Net sales 166.4 179.1 +7.7%
EBITDA (*) 18.3 27.0 +48%
EBITDA margin 11.0% 15.1%
Current operating income (*) | 8.0 | 15.6 | +95.4% |
Current operating income margin | 4.8% | 8.7% | |
Other operating income and expenses | -2.1 | 0.4 | |
Financial result | -3.3 | -5.1 | |
Taxes | -0.1 | -2.1 | |
Ne t profit a ttributa ble to the Group | 2.5 | 9.0 | |
(*) of which research tax credit (CIR): 3.1 M€ in 2014 and 2015 |
Audit procedures have been performed and auditor's report is in progress of being issued.
Earnings
As of 31 December 2015, the PCAS Group had generated consolidated net sales of €179.1 million up by 7.7 % compared to the same period for the previous financial year (+3.8 % at a constant exchange rate).
After accounting for non-recurring income of €2.9 million net of income and higher finance charges in the period, the PCAS Group's net income stands at €9.0 million in 2015, against €2.5 million in 2014.
Net debt continued to fall, down to €34.7 million as of 31 December 2015 against €48.0 million as of 31 December 2014.
Outlook for the current year
In 2016 the PCAS group forecasts an increase in sales, excluding external growth, in all its operations, which should lead to a new improvement in the results.
The PCAS group has the necessary resources to continue implementing its ambitious investment program and is considering external growth opportunities.
Dividend
Under those circumstances, the Board of Directors will ask the next Shareholder's Meeting to approve payment of a dividend of 0.12 Euros per share (including the interim dividend of 0.06 Euros per share paid in September 2015).
Next meeting: |
2016 Shareholder's Meeting in Longjumeau at 10 a.m. on April 21, 2016 |
PCAS specialises in the development and production of complex molecules for Life Sciences and Innovative Technologies. With 7% of its turnover dedicated to R&D and a wide international presence, PCAS is the preferred industrial partner of market-leading major global groups. The company offers a growing range of proprietary products and solutions in leading-edge segments, and also includes two subsidiaries with very strong potential: Protéus in biotechnology and Enersens in high-performance insulation. With a particularly high standard of performance, PCAS achieved net sales of €179,1 million in 2015 and employs nearly 900 people in six countries.
For more information about PCAS: www.pcas.com
PCAS | NewCap |
Vincent Touraille / Eric Moissenot PCAS | Emmanuel Huynh NewCap Financial Communication & investors relations |
Tel. : +33 1 69 79 61 32 www.pcas.com | Tel. : +33 1 44 71 94 94 pcas@newcap.eu |
PCAS SA issued this content on 18 February 2016 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 18 February 2016 16:52:07 UTC
Original Document: http://www.pcas.com/content/download/3332/51987/version/2/file/PCAS résultats 2015 English V3.pdf
